News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moomoo Earnings
This document is a quarterly report (10-Q) filed by Quoin Pharmaceuticals. It contains financial statements and other important disclosures required by the Securities and Exchange Commission for the reporting period.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
(RTTNews) - Quoin Pharmaceuticals Ltd. (QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, reported second-quarter 2026 results and provided a corporate update highlighting progress across its QRX003 and QRX009 platforms. Quoin is developing topical therapies for rare dermatologic conditions, …
Quoin Pharmaceuticals reported key pipeline milestones and its Q2 2026 financial results. The FDA granted conditional approval for QYLEKI™ as the proposed brand name for QRX003, intended for Netherton Syndrome, and cleared the first-ever IND for Peeling Skin Syndrome, enabling a Phase 2/3 study …
Quoin Pharmaceuticals (QNRX.US) is scheduled to release its earnings report on August 14. The announcement will be made before the market opens. Investors and analysts will be closely watching the report for insights into the company's financial performance.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced it will release its second quarter 2026 financial results and provide a corporate update before the market opens on Friday, August 14, 2026. The update will include an operational overview, recent achievements, and financial highlights for the quarter …
Quoin Pharmaceuticals (NASDAQ: QNRX) announced it will provide a corporate update and release its second-quarter 2026 financial results before the U.S. market opens on Friday, August 14, 2026. The update will highlight key achievements, recent accomplishments, and financial performance for the quarter ended June …
This article provides an earnings forecast for Quoin Pharmaceuticals Ltd (QNRX), indicating a current earnings forecast score of 8.00 and an average price target of $30.00 among analysts. Based on ratings from 4 analysts, the stock receives a "Buy" trend recommendation with a significant …
Quoin Pharmaceuticals Ltd (QNRX) is projected to report a loss of $1.61 per share, according to this earnings preview. The article, sourced from Reuters, provides an outlook on the company's upcoming financial performance.
Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome, expanding its lead asset beyond its initial target, Netherton syndrome. This clearance, announced on July 9, 2026, marks a significant regulatory milestone but comes amidst Quoin's disclosed …
This article provides current market data, analysis, and key insights for Quoin Pharmaceuticals Ltd (QNRX). It highlights the company's strong fundamentals, high growth potential, and "Buy" rating from analysts with significant upside potential despite recent stock market performance. The article also details Quoin Pharmaceuticals' …
This article details the shareholder structure of Quoin Pharmaceuticals Ltd (QNRX), identifying its major individual and institutional holders. It provides a breakdown of share proportions by shareholder type and tracks changes in institutional holdings over several quarters. Key information includes top holders like Ikarian …
This article provides historical dividend and stock split information for Quoin Pharmaceuticals Ltd (QNRX). It notes that no dividends have been distributed over the past five years and lists several merger-related stock splits with their respective ex-dividend dates, types, and ratios from 2022 to …
This article provides a technical analysis of Quoin Pharmaceuticals Ltd (QNRX), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.14 within the Biotechnology & Medical Research industry, …
This article provides a financial health analysis of Quoin Pharmaceuticals Ltd (QNRX), indicating its current financial score is 6.96, ranking 175 out of 386 in its industry, with robust financial status but low operating efficiency. The analysis highlights various financial dimensions like Quality of …
The article provides the enterprise value to EBITDA forward for Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX). It indicates the trading view and financial metrics for the company. The content appears to be a stub or a placeholder from a financial data platform, providing limited specific …
This article displays the cash flow from financing activities for Quoin Pharmaceuticals. Ltd Sponsored ADR (LS:A41BEM) on TradingView. It provides a placeholder for financial data ("Period Value Change Change %") related to this specific financial metric. The page is part of the extensive financial …
This page provides financial data for Quoin Pharmaceuticals. Ltd Sponsored ADR (LSX:A41BEM), specifically focusing on its operating expenses excluding the cost of goods sold. The information is presented by TradingView and includes details on the company's performance on the Lang & Schwarz Exchange.
Insiders at Quoin Pharmaceuticals, who collectively invested US$128.6k at an average price of US$8.49 per share over the last year, have seen their investment value drop to US$63.8k due to an 11% price decline. The biggest single purchase was by Independent Director Dennis Langer, …
This page provides financial information for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is closed with no current trades. It also details that select market …
This article provides access to the Annual Report to Security Holders (ARS) for Quoin Pharmaceuticals. The report is a crucial document for investors and stakeholders, offering a comprehensive overview of the company's financial performance and operational activities over the past year.
Quoin Pharmaceuticals will hold its 2026 Annual General Meeting on August 20, 2026, where shareholders will vote on five key proposals, including the election of seven directors, an advisory "say-on-pay" for executive compensation, changes to director compensation, and changes to 401(k) matching contributions. The …
This article announces that Quoin Pharmaceuticals Ltd. has filed Form DEF 14A. The filing date is July 16, and the content includes the form itself along with market data. The article also lists various financial instruments and their current performance, although these appear to …
Search by ticker symbol or company name and select a result to open its chart.